CASTLE BIOSCIENCES INC

CSTL

Held by 2 specialist biotech funds

Share on X

Fund Holdings

RTW Investments Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Position Trend

Feb 13, 2026

$11.9M

1 fund

Feb 17, 2026

$82.3M

1 fund

+593% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

RTW InvestmentsNEWFeb 17, 2026

Shares: 2,115,237Value: $82.3M

# Signal Note: RTW Investments Initiates $82.3M Position in CSTL RTW's substantial entry into Castle Biosciences signals confidence in the company's dermatologic diagnostics portfolio, particularly its melanoma risk stratification tests (DecisionDx-Melanoma) and broader oncology expansion. The timing suggests conviction ahead of potential upcoming data readouts or commercial inflection points, though near-term catalysts (specific trial readouts, reimbursement decisions, or revenue acceleration) should be monitored to validate the thesis.

Eventide Asset ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

IVEVF2 funds QURE2 funds SYK2 funds WVE2 funds CYTK2 funds IRON2 funds CGON2 funds BBNX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Eventide Initiates $11.9M CSTL Position** Castle Biosciences' DecisionDx-Melanoma and DecisionDx-SCC diagnostic platforms address high-margin, recurring-revenue opportunities in melanoma and squamous cell carcinoma risk stratification, with reimbursement stability and expanding clinical adoption as primary value drivers. Eventide's entry—consistent with its values-based biotech focus on differentiated diagnostics—suggests conviction in execution visibility, likely tied to upcoming 2024-2025 revenue inflection from Medicare coverage expansion and international rollout rather than binary clinical catalysts.